Neonates who have had in utero exposures from maternal substance abuse can experience
central nervous system effects of the drugs, including drug toxicity and withdrawal. Neonatal …

Tens of thousands of infants are impacted yearly by prenatal opioid exposure. The term
neonatal opioid withdrawal syndrome (NOWS) is now replacing the more familiar term …

Background Neonatal abstinence syndrome (NAS) includes an array of symptoms impacting
opioid-exposed newborns (OEN) owing to postnatal withdrawal from in utero substance …

Neonatal abstinence syndrome (NAS) comprises a constellation of drug-withdrawal
symptoms that result from chronic intrauterine exposure to a variety of substances, including …

Neonatal withdrawal symptoms have been noted following prenatal exposure to several
drugs. Examples include opioids, 1, 2 benzodiazepines, 3, 4 mood-stabilizing medications …

Neonatal abstinence syndrome refers to the signs and symptoms attributed to the cessation
of prenatal exposure (via placental transfer) to various substances. This Primer focuses on …

Neonatal Abstinence Syndrome | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …

The growing incidence of neonatal abstinence syndrome (NAS) among newborns is a public
health crisis that is a sequela of the national opioid crisis. When fetuses are exposed to …

Neonates exposed prenatally to opioids will often develop a collection of withdrawal signs
known as neonatal abstinence syndrome (NAS). The incidence of NAS has substantially …

Neonatal abstinence syndrome (NAS) secondary to in-utero opioid exposure is an
increasing problem. Variability in assessment and treatment of NAS has been attributed to …